Disease State Management - NAPLEX

1. A 69-year-old woman (72 kg, 160 cm) comes to the pharmacy for medication review. PMH: type 2 diabetes, CKD stage 3b, hypertension. Current meds: metformin 1000 mg PO BID, dapagliflozin 10 mg PO daily, lisinopril 10 mg PO daily. Labs: A1c 7.4%; SCr 1.8 mg/dL (eGFR 28), K 4.9 mEq/L; bicarbonate 23 mEq/L. She has no GI side effects but asks if any medication doses should change due to kidney function. Allergies: none. How should this patient's medication regimen be modified?
   Answer: Discontinue metformin due to eGFR 28 mL/min/1.73 $m^2$ and continue dapagliflozin if tolerated This question tests the management of antidiabetic medications in advanced chronic kidney disease. The key patient-specific factor is the eGFR of 28 mL/min/1.73 m², which contraindicates metformin due to lactic acidosis risk, while dapagliflozin can continue if tolerated. Discontinuing metformin while continuing dapagliflozin aligns with ADA and KDIGO guidelines, as SGLT2 inhibitors provide renoprotection in CKD, supported by DAPA-CKD trial evidence, unlike metformin which is contraindicated below eGFR 30. Continuing or reducing metformin ignores the contraindication and acidosis risk, while discontinuing dapagliflozin to increase metformin forfeits renal benefits and violates safety guidelines. Increasing metformin further exacerbates risks without benefit. For similar CKD cases, regularly reassess medication appropriateness based on eGFR to prevent adverse events. Emphasize patient-centered care by discussing alternatives like insulin if needed and monitoring for euglycemic DKA with SGLT2 inhibitors.
2. A 67-year-old male (weight 76 kg, height 175 cm) presents to urgent care with worsening shortness of breath and increased sputum production for 3 days. Medical history: COPD (GOLD group D), former smoker, hypertension. Baseline COPD therapy: tiotropium inhaler 2 puffs daily and budesonide/formoterol 160/4.5 mcg 2 puffs twice daily; uses albuterol HFA as needed. Current medications: tiotropium, budesonide/formoterol, albuterol HFA, amlodipine 5 mg PO daily. Vitals: SpO$_2$ 90% on room air, RR 22, afebrile. Labs: WBC 12.5 x10$^3$/mcL, SCr 1.0 mg/dL. Allergies: none. Which medication adjustment is most appropriate for this patient's condition?
   Answer: Start prednisone 40 mg PO daily for 5 days and start doxycycline 100 mg PO twice daily for 5 days This question tests the management of acute COPD exacerbation in a patient already on optimal maintenance therapy. The patient presents with increased dyspnea, sputum production, and hypoxemia (SpO2 90%), meeting criteria for a moderate COPD exacerbation requiring systemic corticosteroids and consideration of antibiotics. Starting prednisone 40 mg daily for 5 days with doxycycline (A) is the most appropriate treatment, as guidelines recommend 40 mg prednisone for 5 days for COPD exacerbations, and antibiotics are indicated when increased sputum purulence is present or in moderate-severe exacerbations. Low-dose prednisone for 14 days (B) provides inadequate anti-inflammatory effect and unnecessarily prolongs steroid exposure. Azithromycin alone without corticosteroids (C) fails to address the inflammatory component essential for exacerbation recovery. Discontinuing maintenance therapy (D) would worsen long-term control and montelukast has no role in COPD management. For COPD exacerbations, remember the "5-day/40 mg" prednisone regimen as standard of care, with antibiotics added for purulent sputum or moderate-severe presentations, while maintaining all chronic therapies.
3. A 59-year-old woman (68 kg, 158 cm) is seen for dyslipidemia optimization. PMH: hypertension, prior ischemic stroke (2 years ago). Current meds: atorvastatin 80 mg PO nightly, ezetimibe 10 mg PO daily, aspirin 81 mg PO daily, metoprolol succinate 50 mg PO daily. Labs: LDL 92 mg/dL, TG 130 mg/dL, AST/ALT WNL, SCr 0.8 mg/dL. Allergies: none. Which medication adjustment is most appropriate for this patient's condition?
   Answer: Add a PCSK9 inhibitor (e.g., evolocumab) while continuing high-intensity statin plus ezetimibe This question tests the intensification of lipid-lowering therapy in high-risk patients with prior stroke. The key patient-specific factor is LDL of 92 mg/dL despite high-intensity statin plus ezetimibe, in a patient with ASCVD warranting further reduction. Adding a PCSK9 inhibitor is optimal as ACC/AHA guidelines recommend it for very high-risk ASCVD if LDL >=70 mg/dL on maximal therapy, with FOURIER trial evidence showing CV event reduction. Decreasing atorvastatin ignores guidelines for high-intensity therapy, while switching to niacin adds side effects without superior efficacy. Adding fenofibrate targets triglycerides unnecessarily and lacks LDL focus. For similar high-risk dyslipidemia cases, escalate therapy stepwise to achieve LDL <70 mg/dL. Emphasize patient-centered care by discussing injection administration and monitoring for injection-site reactions to ensure adherence and safety.
4. A 66-year-old man (78 kg, 172 cm) with COPD presents to urgent care with increased dyspnea and sputum volume for 2 days. PMH: COPD (FEV1 45% predicted), HTN. Current meds: tiotropium inhaled daily, albuterol HFA PRN, lisinopril 10 mg PO daily. Vitals: T 37.6°C, HR 98, RR 22, SpO2 90% on room air. No pneumonia on chest X-ray. Labs: WBC 10.8 $x10^3$/µL, SCr 1.0 mg/dL. Allergies: none. What is the optimal therapeutic plan for managing this disease state?
   Answer: Start prednisone 40 mg PO daily for 5 days and add doxycycline 100 mg PO BID for 5 days, plus short-acting bronchodilator optimization This question tests the management of acute COPD exacerbations with increased sputum and dyspnea. The key patient-specific factor is signs of infection (increased sputum, mild fever) without pneumonia, warranting systemic steroids and antibiotics. Starting prednisone and doxycycline with bronchodilator optimization aligns with GOLD guidelines, as short-course steroids reduce recovery time and antibiotics target bacterial causes in moderate exacerbations. Low-dose long-term prednisone risks side effects unnecessarily, while antibiotics alone omit anti-inflammatory benefits. Inhaled fluticasone monotherapy lacks acute relief. For similar exacerbation cases, assess severity and use guideline-directed therapy promptly. Emphasize patient-centered care by educating on early recognition and smoking cessation for safety and prevention.
5. A 70-year-old woman (58 kg, 157 cm) with COPD calls the pharmacy after starting azithromycin 250 mg PO daily for chronic prophylaxis prescribed by an outside provider. PMH: COPD, prolonged QT history, hypomagnesemia. Current meds: fluticasone/salmeterol inhaled BID, tiotropium inhaled daily, albuterol PRN, citalopram 40 mg PO daily, hydrochlorothiazide 25 mg PO daily. Labs today: Mg 1.4 mg/dL (low; normal 1.7–2.2), K 3.4 mEq/L (low). Allergies: none. Which monitoring parameter is crucial for this patient?
   Answer: Baseline and follow-up ECG (QTc) and correction/monitoring of potassium and magnesium This question tests monitoring for QT prolongation in patients on azithromycin prophylaxis for COPD. The key patient-specific factor is history of prolonged QT, hypomagnesemia, and hypokalemia, exacerbated by concomitant QT-prolonging drugs like citalopram. Baseline and follow-up ECG with electrolyte correction is crucial per GOLD and FDA guidelines, as azithromycin can prolong QTc, increasing torsades risk. INR monitoring is irrelevant without warfarin, while digoxin levels are unnecessary. Amylase for pancreatitis is not routine. In similar high-risk cases, prioritize cardiac monitoring before and during therapy. Focus on safety by correcting electrolytes and educating on arrhythmia symptoms for patient-centered care.
6. An 82-year-old woman (60 kg, 155 cm) presents for regimen simplification. PMH: atrial fibrillation, HFpEF, hypertension, GERD, chronic pain. Current meds: warfarin (INR goal 2–3; last INR 3.4), amiodarone 200 mg PO daily, omeprazole 20 mg PO daily, tramadol 50 mg PO q6h PRN, acetaminophen 1000 mg PO TID, furosemide 20 mg PO daily. Labs: SCr 1.0 mg/dL (eGFR 52), AST/ALT WNL. She reports frequent bruising and missed INR appointments. Allergies: none. Which monitoring parameter is crucial for this patient?
   Answer: INR with warfarin dose adjustment and increased monitoring frequency due to interaction with amiodarone This question tests monitoring for drug interactions in elderly patients with atrial fibrillation. The key patient-specific factor is the interaction between warfarin and amiodarone, which potentiates anticoagulation via CYP inhibition, alongside elevated INR of 3.4 and bruising. Increased INR monitoring with dose adjustment is crucial per guidelines from ACCP, as amiodarone can increase INR by 25-50%, necessitating frequent checks to prevent bleeding. Serum amylase for tramadol is unnecessary without pancreatitis symptoms, while daily warfarin peaks/troughs are not standard. Platelet aggregation for aspirin effects misaligns with warfarin's mechanism. For similar interaction cases, anticipate pharmacokinetic changes and adjust monitoring frequency. Emphasize patient-centered care by educating on bleeding signs and adherence to appointments for safety.
7. A 65-year-old woman (90 kg, 167 cm) with type 2 diabetes presents for follow-up. Current meds: metformin 1000 mg PO BID, insulin glargine 20 units SC nightly. Labs: A1c 10.8%; fasting SMBG 210–260 mg/dL. She reports taking insulin "only when sugar is high" and often skips injections due to fear of hypoglycemia. SCr 0.9 mg/dL. Allergies: none. What counseling advice should be prioritized for this therapy?
   Answer: Counsel to use insulin glargine consistently every day at the same time, teach titration based on fasting SMBG, and review hypoglycemia recognition and treatment This question tests adherence counseling for basal insulin in type 2 diabetes with fear of hypoglycemia. The key patient-specific factor is inconsistent insulin use leading to high A1c of 10.8%, driven by misconceptions about hypoglycemia. Counseling on consistent daily use with titration is optimal per ADA guidelines, as basal insulin requires regularity for efficacy, with education reducing fears through recognition and treatment strategies. Intermittent or variable dosing promotes poor control and risks, while stopping metformin removes benefits. Doubling doses sporadically increases hypoglycemia. For similar adherence cases, address barriers like fear with education and self-monitoring. Emphasize patient-centered care by personalizing titration and hypoglycemia plans for safety and confidence.
8. A 56-year-old man (102 kg, 178 cm) presents to the clinic for chronic disease follow-up. He has type 2 diabetes, ASCVD (prior MI), and albuminuric CKD. Current meds: metformin ER 1000 mg PO BID, glipizide XL 10 mg PO daily, lisinopril 20 mg PO daily, atorvastatin 80 mg PO nightly, aspirin 81 mg PO daily. Labs: A1c 9.2%, fasting SMBG 180–220 mg/dL; SCr 1.6 mg/dL (eGFR 48 mL/min/1.73 $m^2$), UACR 420 mg/g; K 4.6 mEq/L; AST/ALT WNL. Allergies: none. Which medication adjustment is most appropriate for this patient's condition?
   Answer: Add empagliflozin 10 mg PO daily and reassess A1c and renal function in 3 months This question tests the management of type 2 diabetes in patients with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). The key patient-specific factors are the presence of prior myocardial infarction, albuminuric CKD with eGFR 48 mL/min/1.73 m², and uncontrolled A1c of 9.2% despite metformin and glipizide. Adding empagliflozin is optimal as SGLT2 inhibitors are recommended by ADA and KDIGO guidelines for cardiorenal protection and glycemic control in such patients, with evidence from trials like EMPA-REG OUTCOME showing reduced CV events and CKD progression. Adding pioglitazone is less appropriate due to risks of fluid retention and heart failure in ASCVD patients, while increasing glipizide heightens hypoglycemia risk in CKD without cardiorenal benefits. Adding saxagliptin lacks the proven cardiorenal protection of SGLT2 inhibitors and requires dose adjustment for eGFR <50. In similar cases, prioritize agents with proven outcomes beyond glycemia, such as SGLT2 inhibitors or GLP-1 RAs, for high-risk patients. Emphasize patient-centered care by monitoring for side effects like genital infections and reassessing renal function regularly to ensure safety.
9. An 81-year-old male (weight 68 kg, height 173 cm) presents to the pharmacy after a fall and reports dizziness and daytime sedation. Medical history: atrial fibrillation, hypertension, chronic low back pain, insomnia, GERD, BPH, CKD stage 3a. Current medications: warfarin (INR goal 2–3; last INR 2.4), metoprolol tartrate 50 mg PO twice daily, lisinopril 10 mg PO daily, tamsulosin 0.4 mg PO nightly, omeprazole 20 mg PO daily, cyclobenzaprine 10 mg PO three times daily, diphenhydramine 50 mg PO nightly, acetaminophen 1000 mg PO three times daily as needed. Labs: SCr 1.3 mg/dL (eGFR 52 mL/min/1.73 m$^2$), potassium 4.4 mEq/L, LFTs WNL. Allergies: none. How should this patient's medication regimen be modified?
   Answer: Discontinue diphenhydramine and cyclobenzaprine due to anticholinergic/sedation risk and recommend nonpharmacologic sleep measures This question addresses polypharmacy and medication safety in an elderly patient following a fall. The 81-year-old patient is experiencing dizziness and daytime sedation, with multiple high-risk medications contributing to fall risk through anticholinergic burden and sedation. Discontinuing diphenhydramine and cyclobenzaprine (B) is the most appropriate intervention as both medications have significant anticholinergic effects and sedation properties, appearing on the Beers Criteria as potentially inappropriate medications in older adults, with safer alternatives available for both insomnia and muscle relaxation. Adding meclizine (A) would worsen anticholinergic burden and sedation without addressing the underlying cause. Increasing tamsulosin (C) could worsen orthostatic hypotension and dizziness. Switching to propranolol (D) doesn't address the primary sedation/anticholinergic issues and propranolol has similar fall risk. In geriatric patients presenting with falls or cognitive changes, systematically review medications for anticholinergic burden, sedation risk, and adherence to Beers Criteria, prioritizing deprescribing of high-risk medications before adding new agents.
10. A 45-year-old female (weight 89 kg, height 160 cm) presents for diabetes follow-up. She admits she often misses doses because of a rotating work schedule and GI upset. Medical history: type 2 diabetes, hypertension, dyslipidemia. Current medications: metformin immediate-release 1000 mg PO twice daily (misses ~5 doses/week), glipizide 10 mg PO twice daily (misses ~3 doses/week), losartan 50 mg PO daily, rosuvastatin 20 mg PO nightly. Labs: A1c 10.2%, fasting glucose 240 mg/dL, SCr 0.8 mg/dL (eGFR 95 mL/min/1.73 m$^2$), ALT/AST WNL. Allergies: none. What counseling advice should be prioritized for this therapy?
    Answer: Recommend switching metformin to extended-release and using a once-daily routine (e.g., with dinner) to improve tolerability and adherence This question evaluates medication adherence strategies in type 2 diabetes management with poor glycemic control. The patient's A1c of 10.2% reflects significant non-adherence, missing approximately 40% of metformin doses and 20% of glipizide doses due to GI upset and complex scheduling with rotating work shifts. Recommending metformin extended-release with once-daily dosing (B) addresses both the GI tolerability issues and simplifies the regimen to improve adherence, as extended-release formulations reduce GI side effects by 50% and once-daily dosing improves adherence compared to twice-daily regimens. Advising glipizide only when skipping meals (A) is dangerous and could cause severe hypoglycemia. Doubling missed metformin doses (C) would worsen GI side effects and doesn't follow safe medication practices. Stopping metformin at first sign of diarrhea (D) would further compromise glycemic control and doesn't address the underlying adherence barriers. When addressing medication non-adherence, identify and systematically address specific barriers (side effects, complexity, scheduling) with evidence-based solutions like extended-release formulations and simplified dosing regimens rather than expecting behavior change alone.
11. A 62-year-old female (weight 74 kg, height 165 cm) is seen in clinic for uncontrolled hypertension. Medical history: hypertension, hyperlipidemia, osteoarthritis; no diabetes; no known ASCVD; nonsmoker. Current medications: amlodipine 10 mg PO daily, hydrochlorothiazide 25 mg PO daily, ibuprofen 600 mg PO three times daily as needed (uses most days). Vitals: average home BP 154/92 mmHg over 2 weeks; HR 78 bpm. Labs: SCr 0.9 mg/dL, potassium 3.6 mEq/L, sodium 140 mEq/L, LDL 156 mg/dL, AST/ALT WNL. Allergies: none. What is the optimal therapeutic plan for managing this disease state?
    Answer: Add lisinopril 10 mg PO daily and counsel to minimize NSAID use due to BP and renal effects This question evaluates the management of uncontrolled hypertension in a patient using chronic NSAIDs. The patient's blood pressure remains elevated (154/92 mmHg) despite two antihypertensive agents, with daily ibuprofen use likely contributing to treatment resistance through sodium retention and blunting of antihypertensive effects. Adding lisinopril (A) is the most appropriate choice as ACE inhibitors are recommended for hypertension management, and counseling to minimize NSAID use addresses the root cause of poor BP control while acknowledging the patient's osteoarthritis needs. Switching to furosemide (B) is inappropriate as loop diuretics are not preferred for uncomplicated hypertension and don't address the NSAID interaction. Clonidine (C) would be premature before optimizing current therapy and addressing NSAID use, and carries sedation risks. Increasing amlodipine to 20 mg (D) exceeds the maximum recommended dose of 10 mg daily. When managing hypertension in patients with chronic pain, always assess NSAID use as a reversible cause of treatment resistance and consider alternative pain management strategies while optimizing antihypertensive therapy with evidence-based agents.
12. A 72-year-old man (76 kg, 170 cm) is seen for medication safety review after starting trimethoprim-sulfamethoxazole for cellulitis. PMH: hypertension, HF with reduced EF, CKD stage 3. Current meds: lisinopril 20 mg PO daily, spironolactone 25 mg PO daily, furosemide 40 mg PO daily. Labs today: SCr 1.5 mg/dL (eGFR 45), K 5.6 mEq/L (high; normal 3.5–5.0). Allergies: none. How should this patient's medication regimen be modified?
    Answer: Hold spironolactone and contact prescriber to change antibiotic and/or urgently address hyperkalemia risk; recheck potassium promptly This question tests the management of hyperkalemia risks from drug interactions in heart failure. The key patient-specific factor is elevated potassium of 5.6 mEq/L with trimethoprim-sulfamethoxazole, which inhibits potassium excretion, compounded by lisinopril and spironolactone in CKD. Holding spironolactone and addressing the interaction is optimal per HF guidelines, as trimethoprim acts like amiloride, necessitating alternative antibiotics or dose holds with prompt recheck. Continuing all risks arrhythmias, while adding potassium worsens hyperkalemia. Increasing lisinopril ignores the acute issue. In similar interaction cases, identify potassium-sparing combinations and intervene urgently. Focus on safety by educating on dietary potassium and symptoms of hyperkalemia for patient-centered care.
13. A 63-year-old man (100 kg, 175 cm) presents for medication safety review. PMH: type 2 diabetes, CKD stage 4, neuropathy. Current meds: gabapentin 600 mg PO TID, metformin 500 mg PO BID, insulin glargine 30 units nightly. Labs: SCr 2.6 mg/dL (eGFR 22), A1c 7.8%. He reports marked daytime sedation and unsteady gait. Allergies: none. How should this patient's medication regimen be modified?
    Answer: Reduce gabapentin dose due to eGFR 22 (e.g., decrease total daily dose and/or extend interval) and reassess sedation and pain control This question tests dose adjustments for gabapentin in advanced chronic kidney disease. The key patient-specific factor is eGFR of 22 mL/min/1.73 m², leading to gabapentin accumulation and symptoms like sedation and gait instability. Reducing the dose is optimal per FDA labeling, recommending lower daily doses or extended intervals for eGFR <30 to mitigate toxicity while controlling neuropathy. Continuing or increasing the dose worsens adverse effects, while switching to pregabalin still requires adjustment. For similar renal impairment cases, calculate adjusted doses using pharmacokinetic data. Emphasize patient-centered care by reassessing symptoms post-adjustment and exploring non-pharmacologic pain options for safety.
14. A 48-year-old man (110 kg, 183 cm) presents for diabetes follow-up. PMH: type 2 diabetes, hypertension. Current meds: metformin ER 1000 mg PO BID, insulin glargine 40 units SC nightly, losartan 50 mg PO daily. Labs: A1c 8.6%; fasting SMBG 90–120 mg/dL, postprandial SMBG frequently 220–280 mg/dL; SCr 1.0 mg/dL (eGFR 92). He denies hypoglycemia. Allergies: none. Which medication adjustment is most appropriate for this patient's condition?
    Answer: Add insulin lispro 4 units SC with the largest meal and titrate based on 2-hour postprandial SMBG This question tests the intensification of insulin therapy in type 2 diabetes with postprandial hyperglycemia. The key patient-specific factor is well-controlled fasting glucose but elevated postprandial SMBG of 220–280 mg/dL, contributing to A1c of 8.6% despite basal insulin and metformin. Adding prandial insulin lispro is optimal as guidelines from ADA recommend adding bolus insulin to target postprandial excursions when basal insulin is maximized without hypoglycemia. Increasing basal insulin glargine primarily addresses fasting glucose, which is already adequate, and may increase hypoglycemia risk, while discontinuing metformin removes a beneficial sensitizer without justification. Switching to NPH offers no advantage over glargine and may worsen control due to peaking action. In similar insulin-requiring cases, use a stepwise approach starting with basal and adding prandial as needed for comprehensive glycemic control. Prioritize patient safety by teaching carbohydrate counting and hypoglycemia management to support self-care.
15. A 64-year-old male (weight 70 kg, height 172 cm) with type 2 diabetes presents for follow-up. Medical history: T2DM, peripheral neuropathy, CKD stage 4, hypertension. Current medications: insulin glargine 24 units subcutaneously nightly, insulin aspart 6 units subcutaneously with meals, gabapentin 300 mg PO three times daily, amlodipine 10 mg PO daily. Labs: A1c 8.8%, fasting glucose 180 mg/dL, SCr 2.8 mg/dL (eGFR 22 mL/min/1.73 m$^2$), potassium 4.9 mEq/L, bicarbonate 22 mEq/L. Allergies: none. Which medication adjustment is most appropriate for this patient's condition?
    Answer: Add dulaglutide 0.75 mg subcutaneously once weekly and titrate as tolerated for additional glycemic lowering and CV benefit This question addresses glycemic management in advanced CKD where medication options are limited. The patient has type 2 diabetes with CKD stage 4 (eGFR 22 mL/min/1.73 m²) and inadequate glycemic control (A1c 8.8%) despite basal-bolus insulin therapy, requiring careful selection of additional agents based on renal function. Adding dulaglutide 0.75 mg weekly (C) is the most appropriate choice as GLP-1 receptor agonists can be used in CKD with dose adjustment (dulaglutide requires no adjustment down to eGFR 15 mL/min/1.73 m²), provide A1c reduction of 1-1.5%, offer cardiovascular benefits, and have low hypoglycemia risk. Metformin (A) is contraindicated with eGFR <30 mL/min/1.73 m². Empagliflozin (B) is not recommended when eGFR <20 mL/min/1.73 m² as glycemic efficacy is lost, though kidney protection may continue. Glyburide (D) should be avoided in CKD due to prolonged half-life and severe hypoglycemia risk. In advanced CKD, medication selection requires careful consideration of renal clearance, with GLP-1 agonists and insulin being the safest options, while most oral agents require significant dose reduction or avoidance.
16. A 58-year-old female (weight 60 kg, height 162 cm) is admitted for treatment of a deep vein thrombosis and is started on unfractionated heparin infusion. Medical history: DVT (new), CKD stage 3b, hypertension. Current medications: heparin infusion per protocol, lisinopril 10 mg PO daily. Labs: SCr 1.9 mg/dL (eGFR 32 mL/min/1.73 m$^2$), baseline hemoglobin 12.8 g/dL, platelets 210 x10$^3$/mcL. Allergies: none. Which monitoring parameter is crucial for this patient?
    Answer: Activated partial thromboplastin time (aPTT) or anti-Xa level per protocol and platelet count every 2–3 days to monitor for HIT This question evaluates appropriate monitoring parameters for unfractionated heparin therapy in a patient with renal dysfunction. The patient has CKD stage 3b (eGFR 32 mL/min/1.73 m²) and is receiving IV heparin for DVT treatment, requiring specific monitoring for both efficacy and safety. Monitoring aPTT or anti-Xa levels per protocol and platelet counts every 2-3 days (B) is essential for heparin management, as aPTT/anti-Xa ensures therapeutic anticoagulation while platelet monitoring detects heparin-induced thrombocytopenia (HIT), which occurs in 0.5-5% of patients typically between days 5-14. Daily potassium monitoring (A) is excessive as heparin-induced hyperkalemia develops gradually over days to weeks. INR monitoring (C) is incorrect as heparin doesn't affect INR; this parameter monitors warfarin therapy. Daily amylase/lipase (D) is unnecessary as heparin-induced pancreatitis is extremely rare. When initiating heparin therapy, establish baseline platelets and monitor every 2-3 days through day 14 or until discontinued, while using aPTT or anti-Xa to guide dosing, particularly important in renal dysfunction where drug accumulation may occur.
17. A 56-year-old male (weight 98 kg, height 178 cm) presents for follow-up of type 2 diabetes. He reports polyuria and fatigue. Medical history: T2DM x 8 years, hypertension, obesity, diabetic kidney disease. Previous treatment: lifestyle changes and metformin; no prior insulin or GLP-1 receptor agonist use. Current medications: metformin ER 1000 mg PO twice daily, lisinopril 20 mg PO daily, atorvastatin 40 mg PO nightly. Labs: A1c 9.4%, fasting glucose 210 mg/dL, SCr 1.6 mg/dL (eGFR 48 mL/min/1.73 m$^2$), potassium 4.6 mEq/L, UACR 220 mg/g, ALT/AST WNL. Allergies: none. Which medication adjustment is most appropriate for this patient's condition?
    Answer: Add empagliflozin 10 mg PO daily for glycemic control and kidney/cardiovascular benefit This question tests the management of type 2 diabetes with diabetic kidney disease and inadequate glycemic control. The patient has an A1c of 9.4% with an eGFR of 48 mL/min/1.73 m², requiring consideration of both glycemic efficacy and renal/cardiovascular benefits when selecting therapy. Empagliflozin (B) is the optimal choice as SGLT2 inhibitors provide glycemic control while offering proven kidney and cardiovascular protection in patients with diabetic kidney disease, with empagliflozin specifically indicated down to eGFR ≥20 mL/min/1.73 m². Pioglitazone (A) would improve glycemic control but lacks the kidney protection benefits and may cause fluid retention, concerning in CKD. Glyburide (C) is inappropriate due to increased hypoglycemia risk in CKD and lack of organ protection benefits. Discontinuing metformin (D) is incorrect as current guidelines support continuation with dose adjustment when eGFR is 30-60 mL/min/1.73 m², and sitagliptin lacks the cardiovascular/renal benefits of SGLT2 inhibitors. When managing diabetes with CKD, prioritize agents with proven kidney and cardiovascular benefits while maintaining glycemic control, making SGLT2 inhibitors or GLP-1 receptor agonists preferred add-on therapies after metformin.
18. A 52-year-old female (weight 66 kg, height 163 cm) presents to the pharmacy with new-onset muscle pain and dark urine 2 weeks after a medication change. Medical history: hyperlipidemia, hypertension. Current medications: simvastatin 40 mg PO nightly (recently increased from 20 mg), amlodipine 10 mg PO daily, hydrochlorothiazide 25 mg PO daily. Labs: CK 2,800 U/L (elevated; normal < 200 U/L), SCr 1.4 mg/dL (baseline 0.8 mg/dL), AST 85 U/L (elevated), ALT 72 U/L (elevated). Allergies: none. Which medication adjustment is most appropriate for this patient's condition?
    Answer: Hold simvastatin and evaluate for rhabdomyolysis; once resolved, restart with an alternative statin with lower interaction risk (e.g., pravastatin or rosuvastatin) at an appropriate dose This question evaluates the recognition and management of statin-induced rhabdomyolysis with drug interaction. The patient presents with classic rhabdomyolysis symptoms (muscle pain, dark urine, CK 2,800 U/L) two weeks after simvastatin dose increase while on amlodipine, a moderate CYP3A4 inhibitor that increases simvastatin exposure and myopathy risk. Holding simvastatin and evaluating for rhabdomyolysis, then restarting with pravastatin or rosuvastatin (C) is the appropriate management, as these statins have minimal CYP3A4 metabolism and lower interaction risk with amlodipine, allowing safe continuation of both cardiovascular medications. Continuing simvastatin with CoQ10 (A) is dangerous with active rhabdomyolysis and CoQ10 lacks evidence for preventing statin myopathy. Increasing to simvastatin 80 mg (B) would worsen toxicity and this dose is restricted due to myopathy risk. Switching to lovastatin (D) maintains the same drug interaction as both simvastatin and lovastatin are CYP3A4 substrates. When prescribing statins, always screen for CYP3A4 interactions, particularly with simvastatin and lovastatin which have dose limits with inhibitors, and recognize that pravastatin and rosuvastatin have the least interaction potential.
19. A 58-year-old man (95 kg, 175 cm) with type 2 diabetes presents for follow-up. Current meds: metformin 1000 mg PO BID, canagliflozin 100 mg PO daily, and dulaglutide 1.5 mg SC weekly. Labs: A1c 6.9%, SCr 1.1 mg/dL (eGFR 80). He reports new genital itching and white discharge for 4 days; afebrile; no dysuria. Allergies: none. What counseling advice should be prioritized for this therapy?
    Answer: Advise good genital hygiene, consider OTC/topical antifungal treatment, and seek care if symptoms persist or recur while continuing SGLT2 inhibitor This question tests the management of genital mycotic infections associated with SGLT2 inhibitor therapy in type 2 diabetes. The key patient-specific factor is new genital itching and discharge in a male patient on canagliflozin, with well-controlled A1c and no signs of systemic infection. Advising hygiene, OTC antifungal, and continuation if symptoms resolve is optimal per ADA guidelines, as these infections are common but often self-limited, with evidence supporting SGLT2 inhibitor benefits outweighing risks in most cases. Stopping canagliflozin assuming DKA is incorrect without acidosis symptoms or confirmation, while increasing the dose would worsen glucosuria and infection risk. Avoiding carbohydrates or discontinuing metformin lacks evidence and overlooks infection management. In similar adverse effect cases, educate on preventive hygiene to minimize recurrence and enhance therapy adherence. Promote safety by advising prompt medical evaluation for persistent symptoms to prevent complications.
20. A 60-year-old man (92 kg, 182 cm) presents with persistently elevated BP. PMH: hypertension, chronic low back pain. Current meds: lisinopril 20 mg PO daily, amlodipine 5 mg PO daily, naproxen 500 mg PO BID (daily use). BP: 154/94 mmHg. Labs: SCr 1.3 mg/dL (baseline 1.0 three months ago), K 5.2 mEq/L. Allergies: none. Which medication adjustment is most appropriate for this patient's condition?
    Answer: Discontinue naproxen if possible and use alternative pain management; recheck SCr and potassium and then optimize antihypertensives This question tests the management of drug interactions affecting renal function and electrolytes in hypertension. The key patient-specific factor is rising SCr and potassium with NSAID use alongside lisinopril, indicating potential acute kidney injury from combined effects. Discontinuing naproxen and reassessing labs is optimal per guidelines from ACC/AHA, as NSAIDs blunt antihypertensive efficacy and increase hyperkalemia risk with ACE inhibitors. Increasing lisinopril worsens risks without addressing interaction, while adding spironolactone immediately heightens hyperkalemia. Adding potassium chloride is contraindicated with elevated levels. In similar interaction cases, identify and eliminate offending agents first before optimizing therapy. Focus on safety by recommending non-NSAID pain alternatives and close monitoring for patient-centered care.

Start this quiz